U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Noebels JL, Avoli M, Rogawski MA, et al., editors. Jasper's Basic Mechanisms of the Epilepsies. 5th edition. New York: Oxford University Press; 2024. doi: 10.1093/med/9780197549469.003.0069

Cover of Jasper's Basic Mechanisms of the Epilepsies

Jasper's Basic Mechanisms of the Epilepsies. 5th edition.

Show details

Chapter 69Management of Febrile Status Epilepticus

Past, Present, and Future

and .

Abstract

The majority of seizures that arise with fever in infants and children are brief and cause few long-term consequences. A subset of the seizures is prolonged and, when lasting >30 minutes, are termed febrile status epilepticus (FSE). Human and experimental animal data indicate that FSE may be associated with injury to the hippocampus and subsequent temporal lobe epilepsy (TLE) and cognitive problems. Current clinical approaches in the treatment of febrile seizures recommend administration of benzodiazepines to abort the seizure and prevent the evolution of FSE. However, the minimal duration of FSE that leads to epilepsy and memory deficits is unclear, and the first FSE in a child—which is sufficient to provoke long-term consequences—is often difficult to anticipate and abort. Ongoing human and experimental animal studies are beginning to uncover the mechanisms by which FSE can lead to injury, epilepsy, and cognitive deficits in both normal and predisposed individuals. These mechanisms include neuroinflammation and large-scale changes in neuronal gene expression and synaptic connectivity within hippocampal circuits. Future therapy will focus on aborting adverse FSE-induced consequences using mechanism-based interventions.

Introduction

Febrile seizures are one of the most common form of seizures, and 2%–5% of young children in Western countries experience at least one before the age of 6 (Stafstrom, 2002). These seizures should occur in children without a history of neurological illness (AAP Subcommittee on Febrile Seizures, 2008), but the exclusion of neurodevelopmental delay is not explicit. Febrile seizures take place in the setting of a febrile illness without acute electrolyte imbalance or central nervous system infection (AAP Subcommittee on Febrile Seizures, 2008). When the seizures are brief and nonfocal, they are classified as simple febrile seizures and are considered generally benign. The recommendations are to warn parents about the risk of repeat seizures with future febrile illnesses, and children are sent home from the emergency department without workup or further neurological follow-up (Steering Committee on Quality Improvement and Management: Subcommittee on Febrile Seizures, 2008). However, when a febrile seizure is long, lasting over 30 minutes, it is then classified as febrile status epilepticus (FSE) (although alternative definitions exist; Trinka et al., 2015). These children may be at significant risk of long-term neurological consequences (S. Seinfeld et al., 2016). FSE is often focal (though focality is not a requirement) and is frequently the first febrile seizure (Shinnar et al., 2008). Notably, FSE should be distinguished from new-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES) (Gaspard et al., 2018; Hirsch et al., 2018). Whereas FSE is less common than simple febrile seizures, it accounts for 5%–9% of all febrile seizures and affects 25,000–30,000 children per year (Berg and Shinnar, 1996; Hesdorffer et al., 2011; Shinnar et al., 1997). Thus, it is critical to develop an understanding of both the management recommendations of FSE as well as the current research on strategies to prevent long-term consequences.

It is often difficult to separate the relative contribution of genetics and environmental factors in the development of FSE. Genetic predisposition to prolonged febrile seizures and FSE is exemplified by Dravet syndrome, often resulting from a mutation in SCN1A, a gene encoding the alpha subunit of the voltage-gated sodium channel NaV1.1. A long febrile seizure is often the first manifestation of Dravet syndrome and occurs during the first months of life (Hirose et al., 2013; Scheffer and Nabbout, 2019). Other monogenic mutations such as PCDH19 may also present with long FS (Trivisano and Specchio, 2019), and familial associations indicate a genetic component in many infants and children with FS and FSE (Kasperavičiūtė et al., 2013). Studies on twins also support a strong concordance of the genetic influence on the development of FSE, although that relationship is less strong than genetic concordance of simple febrile seizures (Eckhaus et al., 2013; S. A. Seinfeld et al., 2016). Of note, many children have no family history of FSE and a normal prior development, supporting a robust environmental contribution to FSE and its consequences. The contributions of environmental factors to the development of FSE are also well established, with relative temperature of the fever and the type of viral source of fever seeming to play a role (Chin et al., 2006; Mohammadpour Touserkani et al., 2017; Theodore et al., 2008). It is likely that genetic and environmental factors both play a role in the development of FSE, and the spectrum of their relative contributions varies among individuals.

Outcomes Following Febrile Status Epilepticus: Risk of Epilepsy

As mentioned above, individuals who experience simple febrile seizures have an excellent prognosis, both acutely and long term. There is a slightly increased risk of epilepsy, with a lifetime risk of 2%, compared to 1% in the general population (Annegers et al., 1987), and there has been an association with increased risk of psychiatric disease (Dreier et al., 2019), but intellectual development in general is normal (Baram and Shinnar, 2001; Chang et al., 2001; Verity et al., 1998; Vestergaard et al., 2007). This contrasts with the risks after FSE, which has a more guarded long-term prognosis. The short-term outcome following an episode of FSE is good, with a low risk of morbidity and mortality (Chungath and Shorvon, 2008; S. A. Seinfeld et al., 2016). In the long term, the risk is greater. In a child who has a single episode of FSE, the risk of epilepsy increases from 1% to up to 30%–40% (Annegers et al., 1987; Yokoi et al., 2019). Whereas the risk for epilepsy is higher in individuals with abnormal development at the time of the FSE, the increased risk (estimated at 14%; Mewasingh et al., 2020; Pujar et al., 2018) extends to children with no evidence of brain disease. The spontaneous, unprovoked seizures develop years after the initial FSE and may be generalized (Annegers et al., 1987) or originate from the temporal lobe (Abou-Khalil et al., 1993; French et al., 1993). Temporal lobe epilepsy (TLE) is characterized by seizures involving the hippocampus and is often associated with cognitive and emotional problems (Beghi et al., 2006; Nickels et al., 2016). TLE is often difficult to control with antiseizure medication, with ~30% of patients continuing to have seizures even with optimal medication management (Berg, 2008; Chen et al., 2018; Jobst and Cascino, 2015; Spencer, 2002; Wiebe et al., 2001). This makes understanding the mechanisms for FSE-related epileptogenesis important, because they hold the key for preventing the contribution of FSE to the development of TLE.

Prospective studies allow us to more clearly understand the long-term changes in the brain that occur following FSE. The largest of these studies is the ongoing FEBSTAT study, which has been following 199 children from the onset of FSE. It is the first prospective study of its size and combines early brain imaging, cognitive, and medical outcome measures. Due to the long timeline between the FSE and epileptogenesis, analysis of epilepsy outcomes is ongoing, but the project has published on the other long-term effects of FSE, including hippocampal injury (Lewis et al., 2014; McClelland et al., 2016; Provenzale et al., 2008; Shinnar et al., 2012).

Even in prospective studies, it is difficult in children to fully separate the contribution of FSE to epilepsy from the contributions of genetic factors and other inherent predispositions to both FSE and TLE. Experimental models can reveal clear causal relationships and may identify the responsible mechanisms. Several models of FSE have been reported in both mice (Chen et al., 2021; Tao et al., 2016; van Gassen et al., 2008) and rats (Baram et al., 1997; Dubé et al., 2010; Heida et al., 2004; Heida and Pittman, 2005; Reid et al., 2013; Scantlebury et al., 2005). Our immature rat model of experimental (e)FSE leads to limbic epilepsy (Dubé et al., 2006, 2010), allowing for further investigation into the potential mechanisms by which FSE promotes epilepsy. One-third of rats that undergo eFSE develop epilepsy, and epilepsy never develops in controls (Dubé et al., 2006, 2010), supporting the hypothesis that FSE alone is sufficient to induce epilepsy in an otherwise normal brain (Dubé et al., 2006, 2010; Choy et al., 2014).

Outcomes Following Febrile Status Epilepticus: Cognitive Deficits

It has long been understood that epilepsy provoking insults in adults can lead to functional neuropsychiatric changes, including deficits. However, it has been less clear whether SE and FSE contribute to outcome in children. Indeed, the preponderance of evidence in children suggests that the outcome of SE depends on its etiology (S. Seinfeld et al., 2016). There have also been studies showing an increased risk of schizophrenia and mood disorders following febrile seizures (Dreier et al., 2019). Prospective studies such as the FEBSTAT and the North London Study now provide evidence that FSE may lead to long-term cognitive deficits (Jobst et al., 2019; Martinos et al., 2012; Mewasingh et al., 2020; Shinnar et al., 2012). Importantly, cognitive deficits in children can arise following FSE prior to, and thus independent from, spontaneous seizures. Specifically, children tested 6 weeks and 1 year following FSE exhibited deficits in language, motor, and cognitive functions, even when they had no known developmental delays prior to FSE (Martinos et al., 2013; Weiss et al., 2016). This supports the hypothesis that FSE alone is sufficient to induce cognitive deficits, though it is possible that aberrant changes to the limbic/hippocampal networks underlie both the cognitive deficits and TLE. When these same children were given memory and intelligence question (IQ) test 10 years after FSE, they revealed decreased IQ compared to controls, but they did not identify memory problems (Martinos et al., 2019). The authors hypothesize that the normalization in memory together with decrease in IQ is due to differences in the memory strategies tested between the toddlers and older children.

Work in animal models of FSE has recapitulated the data found in children and has provided potential mechanisms. Rats that undergo eFSE early in life have deficits in their performance on the Morris Water Maze (Dubé et al., 2009) and active avoidance task (Patterson et al., 2017) compared to littermate controls. Notably, these deficits are independent of the development of epilepsy. These findings support the notion that FSE directly provokes enduring cognitive deficits, separate from epileptogenesis and independent of genetic contributions. Recent data from the FEBSTAT study have found significant overlap between the children with long-term memory problems and those with hippocampal injury apparent on neuroimaging following FSE (Jobst et al., 2019; Weiss et al., 2017), supporting the hypothesis that FSE may injure hippocampal circuits, inducing memory problems.

The contrast between the good short-term outcomes for children who experience FSE and the guarded long-term prognosis provides incentive for both acute management of FSE and the development of preventative treatments. The ideal management will include the combined strategies of aborting FSE to minimize damage and an intervention to prevent circuit changes within the limbic system that lead to TLE and cognitive deficits.

Pharmacologic Management of FSE: Past and Present

Treatment strategies for FSE have been based on two goals: stopping the seizure acutely and preventing the child from having repeat episodes of FSE (Fig. 69–1). The first step in seizure management prioritizes the ABCs of critical care: maintaining airway, breathing, and circulation; and then administration of a drug to abort the seizure (S. Seinfeld et al., 2016). Similar to afebrile seizures, benzodiazepines (BZDs) are widely accepted as the mainstay first-line medication for any febrile seizure lasting longer than 5 minutes (Chamberlain et al., 2014; Glauser et al., 2016; Silbergleit et al., 2012). If possible, this is best done in an emergency medical services setting, before the child arrives at hospital, though local regulations for BZD administration by emergency medical services vary (Silverman et al., 2017). To minimize time to treatment, minimally invasive routes of medication administration have been the focus of recent studies, especially when evaluating treatment in a prehospital setting. This has been supported in recent studies comparing midazolam to diazepam (which has been found to be similar in its IV form to IV lorazepam) (Chamberlain et al., 2014). The studies revealed similar rates of attaining seizure control between both buccal and intranasal midazolam and intravenous (IV) diazepam, and buccal midazolam was superior to rectal diazepam (Lahat et al., 2000; Nakken and Lossius, 2011; Scott et al., 1999). Interestingly, both buccal and intranasal midazolam achieved faster seizure control as compared to IV diazepam. This supports the argument that medical professionals should not wait for IV access for administration of BZDs during a prolonged febrile seizure, as noninvasive midazolam is comparable, if not superior, at quickly achieving seizure cessation. This is particularly important because a recent study found that delay of first-line BZD treatment of greater than 10 minutes after seizure onset in children is associated with increased risk of negative outcomes, including need for continuous infusions and even death (Gaínza-Lein et al., 2018). Achieving this sub-10-minute goal may require changes in the management and norms of emergency medical services, as is apparent in the FEBSTAT study cohort, where the median time to medication administration was 30 minutes after the seizure onset (Seinfeld et al., 2014). More recent studies have found an average of 15–20 minutes to first BZD administration, but that the timeline did not decrease following society guidelines emphasizing rapid administration (Sánchez Fernández et al., 2020). Additionally, an emerging consensus suggests that the onset of injury that might lead to epilepsy or cognitive problems is earlier than 30 minutes (Joshi and Goodkin, 2020; Sánchez Fernández et al., 2020). The most recent recommendations from the American Epilepsy Society recommend BZDs as first-line treatment, with the highest level of evidence supporting IV diazepam or IV lorazepam, and good evidence supporting the use of rectal diazepam, intramuscular midazolam, intranasal midazolam, and buccal midazolam (Glauser et al., 2016).

Figure 69–1.. Overview of acute management strategies of febrile status epilepticus.

Figure 69–1.

Overview of acute management strategies of febrile status epilepticus.

If seizure cessation cannot be achieved with BZD treatment, administration of additional medication is required, but there is less consensus on the best method. The 2016 status epilepticus guidelines of the American Epilepsy Society recommend either IV valproic acid, fosphenytoin, or levetiracetam, but state there is no clear evidence supporting one option over another (Glauser et al., 2016). A more recent retrospective study found similar efficacy in aborting seizures between IV fosphenytoin and continuous IV midazolam, though IV midazolam decreases likelihood of the patient requiring barbiturate-induced coma (Nishiyama et al., 2018). The ESETT trial was a randomized, controlled trial comparing second-line treatment in children with SE with IV fosphenytoin, levetiracetam, and valproic acid. They found similar seizure control among the three medications, but increased requirement for endotracheal intubation with fosphenytoin compared to the others (Chamberlain et al., 2020; Kapur et al., 2019).

When FSE fails to respond to first- and second-line therapies, it is categorized as refractory FSE. It should also be noted that electrographic epileptic activity may continue without clinical manifestations, suggesting the need for vigilance and additional electroencephalograms (EEGs) if subclinical seizures are suspected (Zehtabchi et al., 2020). A study found that continuous midazolam is inferior to barbiturate coma therapy with continuous EEG in children with refractory FSE, as patients treated with continuous midazolam are more likely to have breakthrough seizures and have worse functional outcomes 1 month after seizure onset (Nagase et al., 2014). Mild hypothermia (32ºC–35ºC) has been used as a treatment to decrease seizure burden in pediatric refractory status epilepticus, but it has not been systematically studied and remains experimental (Guilliams et al., 2013). The American Epilepsy Society does not have a recommendation of the best treatment for refractory FSE based on insufficient research comparing treatments (Glauser et al., 2016).

The required workup following FSE of infectious cause of the fever has been debated. By definition, simple febrile seizures and, by extension, FSE cannot occur in a child with a known central nervous system infection. SE with fever has been shown to be the only clinical symptom of bacterial meningitis (Chin et al., 2005, 2006), and thus there have been studies investigating the value of lumbar puncture in a child with fever, SE, and no meningeal signs. A study of children that received lumbar puncture after FSE found that status epilepticus is rarely the sole presenting symptom of bacterial meningitis in well-vaccinated communities and that lumbar puncture rarely changed diagnosis or management (Haro et al., 2018). There has been previous work revealing patients can have cerebrospinal fluid (CSF) pleocytosis following status epilepticus independent of meningitis or encephalitis (Barry and Hauser, 1994). Contrasting to this long-held belief, the FEBSTAT study found that pleocytosis was very uncommon following FSE, leading to the recommendation against abnormal CSF values after FSE being attributed to a postictal phenomenon alone and that they require careful investigation (Frank et al., 2012). An important consideration when evaluating the utility of lumbar puncture following FSE is the vaccination status of the community and individual patients, as the bacterial conjugate vaccine was first made available in the year 2000. Because of this, there has been a decrease in bacterial meningitis in this age group, decreasing the positive predictive value of pleocytosis and probability of CSF findings changing management (Haro et al., 2018). Accordingly, the recommendation of whether to pursue a lumbar puncture in a child with FSE is up to the individual clinician based on suspicion of meningitis or encephalitis. Pretest probability of an infectious pleocytosis in a lumbar puncture is low without meningeal symptoms in a patient age >12 months and up-to-date vaccinations (S. Seinfeld et al., 2016).

Reoccurrence rate of FSE is high, estimated at over 40% for another episode of any type of febrile seizure and a 10% chance of another episode of FSE (Hesdorffer et al., 2016). Because of this, there has been significant investigation into the utility of prophylactic intermittent or continuous drug treatment to prevent recurrent febrile seizures, with less work focusing specifically on children who have had FSE. Studies have looked at multiple time points and treatment strategies: antipyretic or prophylactic BZD use in current febrile illness, intermittent antipyretics or BZDs at onset of future febrile illnesses, and continuous antiseizure medication throughout the years the child is at risk of febrile seizures (Fig. 69–2). They have shown decreased risk of recurrent febrile seizures with continuous antipyretic use throughout the current illness, but there is no evidence to support continuous antipyretic use in future seizures (Hashimoto et al., 2021; Murata et al., 2018). Previously, the Japan Society of Child Neurology recommended immediate administration of prophylactic BZD to children presenting to the hospital following febrile seizures (Fukuyama et al., 1996). This guideline was changed in 2015, and recent retrospective studies reviewing outcomes of children prior to and following that change revealed that the reduction in prophylactic BZD use correlated with an increase in febrile seizures during the next 24 hours (Inoue et al., 2020). Thus, there may be some role in short-term prophylactic usage of BZD following febrile seizures in children particularly at risk of recurrence.

Figure 69–2.

Figure 69–2.

Overview of prophylactic treatment strategies for prevention of recurrent seizures following febrile seizures

Work investigating continuous phenobarbital prophylaxis or intermittent diazepam prophylaxis only during future febrile illnesses revealed a reduction in reoccurrence of febrile seizures with both treatment strategies. There was no similar benefit of intermittent antipyretics or the other antiseizure medications tested. Importantly, up to 30%–36% of the children in the intermittent BZD- and phenobarbital-treated groups experienced significant cognitive side effects compared to controls (Offringa et al., 2017). Other studies looked at efficacy of other mechanisms of prophylaxis, including intermittent melatonin, but these need to be studied in larger populations (Barghout et al., 2019).

Thus, based on the potential side effects of long-term or intermittent treatment with these medications, it is not recommended to widely prescribe them prophylactically. While it is not recommended to attempt to prevent all febrile seizures, there is risk of repeat FSE, which does entail increased risk. Thus, it is recommended that parents of children who experience FSE be prescribed a noninvasive BZD, such as rectal diazepam, to abort future prolonged febrile seizures (O’Dell et al., 2005).

Neuroimaging after FSE to Predict Clinical Outcomes

Since the development of epilepsy and cognitive problems affect a subset of individuals that experience FSE, there has been significant investigation into developing a method to prognosticate long-term outcomes. These have included clinical, laboratory, and neuroimaging techniques. For example, Nagase et al. found that the combining measures of seizure response to treatment, neurological function 6 hours after seizure onset, and aspartate aminotransferase laboratory values, they were able to retrospectively predict outcomes at discharge (Nagase et al., 2013). More encouraging than combined laboratory measurements is direct measurement via visualization and quantification of brain structures through neuroimaging. Neuroimaging has become the primary method of measuring brain injury following FSE, particularly utilizing magnetic resonance imaging (MRI). MRI is widely clinical available, noninvasive (although requiring anesthesia), and can provide a direct reflection of underlying brain alterations.

Post-FSE imaging has found a higher preponderance of developmental structural changes in children with FSE that likely influenced the brain’s susceptibility to FSE, most specifically hippocampal malrotation (Chan et al., 2015), as well as temporal lobe and hippocampal size abnormalities (McClelland et al., 2016). Additionally, both children and experimental animal models have revealed increased T2 signals throughout the limbic system, and especially the hippocampus, days, weeks, and months after FSE, which likely reflect long-term injury (Dubé et al., 2004; Scott et al., 2003). Most exciting for prognostication is not the differences that were there long before or after FSE, but instead the changes measurable in the hours to days following FSE. These short-term MRI changes reflect the immediate effects of the insult, ideally giving a window into understanding the mechanisms of long-term changes to neuronal circuitry.

Early MRI changes in the brains of rats that undergo eFSE have proven particularly fruitful in predicting epileptogenesis. MRIs 2–6 hours after eFSE in immature rats revealed apparent decrease in T2 values throughout the limbic circuit and especially in hippocampus and amygdala. Remarkably, reduced T2 values within the basolateral amygdala (BLA) were strongly predictive of the subsequent development of epilepsy (Choy et al., 2014). This signal change was initially found on an 11.7T high magnetic field T2 MRI and was a T2* effect, which correlates with changes in deoxyhemoglobin (Chavhan et al., 2009). Using appropriate T2* sequences, these changes are measurable on lower strength scanners as well (Curran et al., 2018). Whether this approach predicts epileptogenesis in children is under current investigation.

Currently published clinical studies in children have analyzed MRIs days, rather than hours, following FSE and have begun to find important differences. A recent study found hippocampal hyperintensity in 27% of children in the days following FSE, which correlated with continued ipsilateral EEG changes after the cessation of FSE. The children who had hippocampal hyperintensity were significantly more likely to develop epilepsy when followed 13 years later than those without (Yokoi et al., 2019). The FEBSTAT study found increased hippocampal T2 signal following FSE in 12% of subjects 24–72 hours after seizure onset, though these changes have not yet been correlated with future risk of epilepsy (Lewis et al., 2014; Shinnar et al., 2012). The group did find that the hippocampi with increased T2 signal in the days following FSE shrank in the year following the seizure, meeting criteria for hippocampal sclerosis, an important risk factor for TLE (Lewis et al., 2014).

In addition to predicting future development of epilepsy, MRI changes have also been associated with future cognitive deficits. Animal models have revealed that T2 increases after eFSE are associated with impaired performance on active avoidance spatial task weeks later, specifically in the hippocampus and basolateral amygdala (Barry et al., 2015). Similarly, results from the FEBSTAT study have revealed that children with increased T2 in the days following FSE were more likely to develop deficits in receptive language skills (Weiss et al., 2016) and memory function (Jobst et al., 2019; Weiss et al., 2017).

Future Treatments to Prevent Long-Term Neurological Changes Following FSE

The ability to predict which children are at risk for both epilepsy and cognitive deficits following FSE is important for counseling families with an accurate prognosis, but it is also critical for the study of the pathogenesis of those changes. Optimally, these predictions should be coupled with treatments aimed at preventing the processes culminating in spontaneous seizures or cognitive problems.

As a result of their role in the production of fever, inflammatory processes are inherently involved in the development of febrile seizures (Dubé et al., 2005; Eskilsson et al., 2014; Heida et al., 2009; Luheshi et al., 1997). Inflammatory modulators signal the hyperthermia that increases excitability of the brain and also have a direct role in increasing the likelihood of spontaneous seizures form the limbic circuit (Dubé et al., 2007; Patterson et al., 2015; Vezzani et al., 2011). Increased levels of inflammatory cytokines are also involved in epileptic seizures and have been measured in the brain of epileptic animals and in the brain tissue removed from patients with epilepsy (Aronica and Gorter, 2007; Balosso et al., 2013). Thus, inflammatory modulators are an enticing candidate for mediating the effects of FSE on both epileptogenesis and cognitive deficits.

In experimental models, increased expression of inflammatory cytokines is fairly rapid, measurable as early as 1 hour after the end of FSE and nearly completely disappearing by 96 hours post seizure (Dubé et al., 2010; Patterson et al., 2015). This rapid time course is encouraging because it allows for potential interventions early in the cascade, rather than interacting with the multitude of long-lasting downstream targets. In immature rodent models inflammatory processes increased most in the same limbic regions and in the same animals in which the epilepsy-predictive MRI signal was observed (Choy et al., 2014; Patterson et al., 2015). The increasing inflammatory mediators in one model included COX2, GFAP, TNF-α, Interleukin-1β (IL-1β), and Interleukin-1 Receptor 1 (IL-1R1) (Patterson et al., 2015). Without this increase in inflammation within the brain, particularly IL-1β, the brain is significantly more resistant to febrile seizure, as seen in mice deficient in IL-1β (Dubé et al., 2005). In other models, TNF-α was the predominant governor of future hyperexcitability (Heida and Pittman, 2005; Reid et al., 2013).

Similarly in children, increases in cytokines and chemokines have measured in the plasma and CSF following FSE, including TNF-α, CXCL9, CXCL10, CXCL11, and CCL19. The levels were increased not only compared to controls but also as compared to children who have experienced afebrile status epilepticus or chronic seizures (Ichiyama et al., 2008; Kothur et al., 2019). Interestingly, the FEBSTAT study found that IL-6 and IL-8 were significantly higher in the serum of patients that had exhibited T2 hippocampal hyperintensity on MRI following FSE, supporting the hypothesis that MRI changes and inflammatory markers measure overlapping processes inherent in epileptogenesis.

Inflammation is also an enticing target for treatment because of the many drugs that are clinically available or in development that directly interact with the inflammatory cascade. There have been studies that investigate the involvement of specific pathways, including IL-1β (Feng et al., 2016; Maroso et al., 2011; Noe et al., 2013; Ravizza et al., 2008), the cyclooxygenase and prostaglandin cascade (Holtman et al., 2010; Järvelä et al., 2011; Jiang et al., 2010, 2012, 2015; Polascheck et al., 2010; Rojas et al., 2014), high mobility group box 1 (HMGB1), a DNA binding protein critical for the initiation of the inflammatory cascade (Brennan et al., 2021; Choi et al., 2011; Li et al., 2013), and micro-RNA 124 (Brennan et al., 2016). Because of the complex and diverse inflammatory cascades involved, it is not surprising that the goal of preventing hyperexcitability following FSE has not been accomplished by blocking single inflammatory pathways. Rather, a short-term treatment with dexamethasone, a clinically available glucocorticoid receptor agonist which acts as a broad anti-inflammatory agent, has proven the most effective at preventing aberrant hippocampal hyperexcitability following FSE, as measured via EEG spike series, a precursor to spontaneous seizures (Garcia-Curran et al., 2019). These findings in experimental models are consistent with a clinical retrospective study that found that children with fever and refractory SE who received methylprednisolone (a similar glucocorticoid receptor agonist) and IV immunoglobulin (IVIG) had better short- and long-term outcomes than children who received IVIG alone or no immunotherapy (Lin et al., 2018).

In addition to provoking inflammatory changes, FSE may influence brain function via enduring changes in gene expression. A deleterious effect of FSE on cognitive outcomes might be a result of such enduring epigenetic processes. Animal experiments have begun to elucidate the potential mechanisms, and thus possible interventions, of these cognitive deficits. Transcriptomic analyses on the brains of rats that underwent eFSE revealed coordinated changes in the expression of multiple genes that govern neuronal behavior. The regulated genes included Neuron-Restrictive Silencing Factor (NRSF), a gene that was originally described in nonneuronal tissues where it played role suppressing neuron-specific genes (Chen et al., 1998; Schoenherr and Anderson, 1995). Since then, NRSF regulation has been shown to play an important role in both developing and mature neurons, including via suppressing genes during neuronal growth and maturation (Ballas and Mandel, 2005; Gao et al., 2011; Singh-Taylor et al., 2017). Seizures increase NRSF protein levels and activity (Brennan et al., 2016; Garriga-Canut et al., 2006; McClelland et al., 2014; Rodenas-Ruano et al., 2012; Roopra et al., 2001), and thus it was hypothesized that NRSF plays a unique role in FSE, due to its dual roles in development and following seizures. Granule cells of the dentate gyrus, a cell population required for learning and memory, are one of the populations of cells that are still differentiating at the developmental period FSE occurs and thus may be uniquely affected (Schlessinger et al., 1975; Thind et al., 2008). Blocking NRSF binding to the chromatin during a few days following FSE rescued the cognitive performance of eFSE rats in an active avoidance learning and memory task in adulthood, significantly better than rats without NRSF blockade (Patterson et al., 2017). The blockade not only prevented memory problems but also rescued the normal development of dentate gyrus granule cells following FSE, suggesting that NRSF regulation following FSE is a promising candidate for treatment (Hall et al., 2018; Patterson et al., 2017).

The Future of FSE and Its Treatment

As we gain a greater understanding of the lifelong effects of even a single episode of FSE, the importance of acute treatment and long-term preventative strategies becomes clear. These strategies are two pronged. First, there are the established first- and second-line treatments to acutely abort prolonged febrile seizures to minimize the seizures’ ability to injure and alter the brain. The second is the true future of FSE management, namely, the accurate prediction of the long-term development of cognitive deficits and epilepsy, and then administration of targeted acute preventative treatments to abort the alterations in brain circuitry before they occur.

The current work studying the mechanisms and treatment strategies in animal models of FSE are the first steps toward future preventative strategies in children and is helping scientists understand the roles of inflammation, epigenetic modulation, and structural brain changes in long-term outcomes. This is critically important because of the major cost of TLE in terms of human potential and productivity. Though modern medicine has reduced the number of individuals that have febrile seizure progress to FSE, FSE is likely to continue as a major source of refractory TLE (Cloppenborg et al., 2019; Englot et al., 2012; Jehi et al., 2015), providing impetus to address its impact on the world’s future generations.

Acknowledgments

The authors’ work has been supported by NIH grants NS35439, NS108296, and T32 NS045540.

References

  1. Abou-Khalil, B., Andermann, E., Andermann, F., Olivier, A., Quesney, L.F., 1993. Temporal lobe epilepsy after prolonged febrile convulsions: excellent outcome after surgical treatment.  Epilepsia 34, 878–83. https://doi​.org/10.1111/j​.1528-1157.1993.tb02105.x [PubMed: 8404740]
  2. Annegers, J.F., Hauser, W.A., Shirts, S.B., Kurland, L.T., 1987. Factors prognostic of unprovoked seizures after febrile convulsions.  N. Engl. J. Med. 316, 493–8. https://doi​.org/10.1056​/NEJM198702263160901 [PubMed: 3807992]
  3. Aronica, E., Gorter, J. a, 2007. Gene expression profile in temporal lobe epilepsy.  Neuroscientist 13, 100–108. https://doi​.org/10.1177/1073858406295832 [PubMed: 17404370]
  4. Ballas, N., Mandel, G., 2005. The many faces of REST oversee epigenetic programming of neuronal genes.  Curr. Opin. Neurobiol.  https://doi​.org/10.1016/j​.conb.2005.08.015 [PubMed: 16150588]
  5. Balosso, S., Ravizza, T., Aronica, E., Vezzani, A., 2013. The dual role of TNF-α and its receptors in seizures. Exp. Neurol.  https://doi​.org/10.1016/j​.expneurol.2013.05.010 [PubMed: 23707217]
  6. Baram, T.Z., Gerth, A., Schultz, L., 1997. Febrile seizures: an appropriate-aged model suitable for long-term studies.  Brain Res. Dev. Brain Res. 98, 265–70. https://doi​.org/10.1016​/S0165-3806(96)00190-3 [PMC free article: PMC3404508] [PubMed: 9051269]
  7. Baram, T.Z., Shinnar, S., 2001. Do febrile seizures improve memory?  Neurology 57, 7–8. https://doi​.org/10.1212/wnl.57.1.7 [PMC free article: PMC3100714] [PubMed: 11445620]
  8. Barghout, M.S., Al-shahawy, A.K., El Amrousy, D.M., Darwish, A.H., 2019. Comparison Between Efficacy of Melatonin and Diazepam for Prevention of Recurrent Simple Febrile Seizures: A Randomized Clinical Trial.  Pediatr. Neurol. 101, 33–38. https://doi​.org/10.1016/j​.pediatrneurol.2019.01.010 [PubMed: 31521449]
  9. Barry, E., Hauser, W.A., 1994. Pleocytosis after status epilepticus.  Arch. Neurol.  https://doi​.org/10.1001/archneur​.1994.00540140100019 [PubMed: 8304844]
  10. Barry, J.M., Choy, M., Dube, C., Robbins, A., Obenaus, A., Lenck-Santini, P.P., Scott, R.C., Baram, T.Z., Holmes, G.L., 2015. T2 relaxation time post febrile status epilepticus predicts cognitive outcome.  Exp. Neurol. 269, 242–252. https://doi​.org/10.1016/j​.expneurol.2015.04.015 [PMC free article: PMC4446141] [PubMed: 25939697]
  11. Beghi, M., Cornaggia, C.M., Frigeni, B., Beghi, E., 2006. Learning disorders in epilepsy.  Epilepsia 47, 14–18. https://doi​.org/10.1111/j​.1528-1167.2006.00681.x [PubMed: 17105453]
  12. Berg, A.T., 2008. The natural history of mesial temporal lobe epilepsy.  Curr. Opin. Neurol. 21, 173–8. https://doi​.org/10.1097/WCO​.0b013e3282f36ccd [PubMed: 18317276]
  13. Berg, A.T., Shinnar, S., 1996. Complex febrile seizures.  Epilepsia 37, 126–133. https://doi​.org/10.1111/j​.1528-1157.1996.tb00003.x [PubMed: 8635422]
  14. Brennan, G.P., Dey, D., Chen, Y., Patterson, K.P., Magnetta, E.J., Hall, A.M., Dube, C.M., Mei, Y.T., Baram, T.Z., 2016. Dual and Opposing Roles of MicroRNA-124 in Epilepsy Are Mediated through Inflammatory and NRSF-Dependent Gene Networks.  Cell Rep. 14, 2402–2412. https://doi​.org/10.1016/j​.celrep.2016.02.042 [PMC free article: PMC4794429] [PubMed: 26947066]
  15. Brennan, G.P., Garcia-Curran, M.M., Patterson, K.P., Luo, R., Baram, T.Z., 2021. Multiple Disruptions of Glial-Neuronal Networks in Epileptogenesis That Follows Prolonged Febrile Seizures.  Front. Neurol. 12, 615802. https://doi​.org/10.3389/fneur​.2021.615802 [PMC free article: PMC7930821] [PubMed: 33679583]
  16. Chamberlain, J.M., Kapur, J., Shinnar, S., Elm, J., Holsti, M., Babcock, L., Rogers, A., Barsan, W., Cloyd, J., Lowenstein, D., Bleck, T.P., Conwit, R., Meinzer, C., Cock, H., Fountain, N.B., Underwood, E., Connor, J.T., Silbergleit, R., Gray, E., Gunter, S., Fansler, A., Stevenson, V., Bengelink, E., Harney, D., Speers, M., Black, J., Fisher, N., Harsh, D., Ramakrishnan, A., Harris, L., Bozeman, N., Spiteri, A., Palesch, Y., Tillman, H., Zhao, W., Pauls, Q., Arnaud, C., Dillon, C.R., Riley, J., Alford, T., Conner, C., Coles, L., Sathe, A., Janis, S., Hartman, A., Fureman, B., Trinka, E., Treiman, D., Wright, D., Ratcliff, J., Hall, A., Williams, A., Simon, H., Stanley, N., Humphries, R., Mims, T., Short, J., Jones, E., Ottman, M., Gentile, N., Isenberg, D., Reimer, H., Sayoc Kalugdan, V., Hemphill, C., Yi Madhok, D., Duncan, J., Randazzo, D., Quinn, J., Visweswaran, A., Mann, R., Adeoye, O., McMullan, J., Foreman, B., Keegan, S., Biros, M., Driver, B., Hendrickson, A., Stang, J., Lewandowski, C., Miller, J., Chaudhry, K., Berry, S., Warden, C., Blake, R., Cook, J.N., Sabolick, E., Selman, A., Kissman, K., Moore, M., Huff, J.S., Becker, L., Claassen, J., Velazquez, A., Falo, C., Coralic, Z., Grupp-Phelan, J., Baren, J., Ellison, A., Woodford, A., Samba, I., Kittick, M., Riviello, R., Massey, J., Bonacquisti, L., Levine, S., Motov, S., Fromm, C., Hossain, R., Likourezos, A., Pushkar, I., Terndrup, T., Khaliqdina, S., Hill, M., Peterson, B., Terwilliger, A., Holm, J., Wicklund, K., Wewerka, S., Welch, R., Pearson, C., Kumar, V.A., Ayaz, F., Bhuiyan, S., Mika, V.H., Morgan, L., Jones, F., Dishman, L., Henry, T., Erickson, F., Staugaitis, A., Lawyer, C., Miller, K., Callaway, C., Urban, A., DiFiore, S., Adams, P., Baum, B., Nomura, J., Davis, B., Aufderheide, T., Emmrich, A., Mena, M., Labinski, J., Ogedegbe, C., McCarthy, D., Villot-Santiago, A., Goldstein, J., Rosenthal, E.S., Cohen, A., Mei Su, C., Tirrell, G., Howell, M., Hendrickson, M., Nerheim, D., Jaton, E., Biney, B., Gibson, C., Dahlmeier, E., Blackburn, K. (Lamond), Vaughan-Ogunlusi, O. (Tim), Zehtabchi, S., Sinert, R., Petty, B., Warden, C., Youngquist, S., Carlson, M., Gilles, N., Weingast, S. (Zelonis), Stern, B., Hopp, J., Ganley, V., Ornato, J., Hogan, C., Payne, A., Shreve, K., Dayan, P., Kuppermann, N., Denninghoff, K., Stanley, R., Ruddy, R., Lerner, E.B., Dean, J.M., Casper, C., Nigrovic, L., Schalick, W., Nelson, D., Thomas, B., Okada, P., Lee, A., Truesdale, N., Chan, S., Naresh, M., Robinson, V., Hwang, J., Carlston, K., Dela Cruz, M., Harbour, T., Karki, R., Cohen, D.M., Nowakowski, A., Lin, C., Fisher Kenny, E., Steele, D., Merck, L.H., Ryan, E., Basso, K., D’Urso, L. (Wasilewski), Brown, K., Nauman, G., Ledda, M., Gillen, S., Grant, V., Vance, C., Nishijima, D.K., Pimenta, K., Herzog, N., Bennett, J., Eisenhart, C., Thomas, D., Wagner, D., Hickey, R.W., Azrak, R., Rubalcava, D., Mondragon, J., Gonzalez, V., Khalil, M., Pearson, C., Kumar, V.A., Hart, K., Parker, S., Lumba, A., Quayle, K., Chinta, S., Robinson, D., Kwok, M., Peery, B., Ochs, J., Suarez, L., 2020. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.  Lancet. 2020 Apr 11;395(10231):1217–1224. doi: 10.1016/S0140-6736(20)30611-5 [PMC free article: PMC7241415] [PubMed: 32203691]
  17. Chamberlain, J.M., Okada, P., Holsti, M., Mahajan, P., Brown, K.M., Vance, C., Gonzalez, V., Lichenstein, R., Stanley, R., Brousseau, D.C., Grubenhoff, J., Zemek, R., Johnson, D.W., Clemons, T.E., Baren, J., 2014. Lorazepam vs diazepam for pediatric status epilepticus: A randomized clinical trial.  JAMA. 2014 Apr 23–30;311(16): 1652–1660. https://doi​.org/10.1001/jama.2014.2625 [PubMed: 24756515]
  18. Chan, S., Bello, J.A., Shinnar, S., Hesdorffer, D.C., Lewis, D. V, MacFall, J., Shinnar, R.C., Gomes, W., Litherland, C., Xu, Y., Nordli, D.R., Pellock, J.M., Frank, L.M., Moshé, S.L., Sun, S., FEBSTAT Study Team, 2015. Hippocampal Malrotation Is Associated With Prolonged Febrile Seizures: Results of the FEBSTAT Study.  AJR. Am. J. Roentgenol. 2015 Nov; 205(5): 1068–74. https://doi​.org/10.2214/AJR.14.13330. [PMC free article: PMC4621774] [PubMed: 26496555]
  19. Chang, Y.C., Guo, N.W., Wang, S.T., Huang, C.C., Tsai, J.J., 2001. Working memory of school-aged children with a history of febrile convulsions: a population study.  Neurology 57, 37–42. https://doi​.org/10.1212/wnl.57.1.37 [PubMed: 11445625]
  20. Chavhan, G.B., Babyn, P.S., Thomas, B., Shroff, M.M., Haacke, E.M., 2009. Principles, techniques, and applications of T2*-based MR imaging and its special applications.  Radiographics 29, 1433–49. https://doi​.org/10.1148/rg.295095034 [PMC free article: PMC2799958] [PubMed: 19755604]
  21. Chen, K.D., Hall, A.M., Garcia-Curran, M.M., Sanchez, G.A., Daglian, J., Luo, R., Baram, T.Z., 2021. Augmented seizure susceptibility and hippocampal epileptogenesis in a translational mouse model of febrile status epilepticus.  Epilepsia 62, 647–658. https://doi​.org/10.1111/epi.16814 [PMC free article: PMC8817061] [PubMed: 33475157]
  22. Chen, Z.-F., Paquette, A.J., Anderson, D.J., 1998. NRSF/REST is required in vivo for repression of multiple neuronaltarget genes during embryogenesis.  Nat. Genet. 20, 136–142. https://doi​.org/10.1038/2431 [PubMed: 9771705]
  23. Chen, Z., Brodie, M.J., Liew, D., Kwan, P., 2018. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study.  JAMA Neurol. 2018 Mar 1; 75(3):279–286. https://doi​.org/10.1001/jamaneurol​.2017.3949 [PMC free article: PMC5885858] [PubMed: 29279892]
  24. Chin, R.F., Neville, B.G., Peckham, C., Bedford, H., Wade, A., Scott, R.C., 2006. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study.  Lancet 368, 222–229. https://doi​.org/10.1016​/S0140-6736(06)69043-0 [PubMed: 16844492]
  25. Chin, R.F.M., Neville, B.G.R., Scott, R.C., 2005. Meningitis is a common cause of convulsive status epilepticus with fever.  Arch. Dis. Child. 90, 66–9. https://doi​.org/10.1136/adc.2003.038844 [PMC free article: PMC1720095] [PubMed: 15613516]
  26. Choi, J., Min, H.J., Shin, J.-S., 2011. Increased levels of HMGB1 and pro-inflammatory cytokines in children with febrile seizures.  J. Neuroinflammation 8, 135. https://doi​.org/10.1186/1742-2094-8-135 [PMC free article: PMC3210097] [PubMed: 21989210]
  27. Choy, M., Dubé, C.M., Patterson, K., Barnes, S.R., Maras, P., Blood, A.B., Hasso, A.N., Obenaus, A., Baram, T.Z., 2014. A novel, noninvasive, predictive epilepsy biomarker with clinical potential.  J. Neurosci. 34, 8672–84. https://doi​.org/10.1523/JNEUROSCI​.4806-13.2014 [PMC free article: PMC4069350] [PubMed: 24966369]
  28. Chungath, M., Shorvon, S., 2008. The mortality and morbidity of febrile seizures.  Nat. Clin. Pract. Neurol.  https://doi​.org/10.1038/ncpneuro0922 [PubMed: 18978801]
  29. Cloppenborg, T., May, T.W., Blümcke, I., Fauser, S., Grewe, P., Hopf, J.L., Kalbhenn, T., Polster, T., Schulz, R., Woermann, F.G., Bien, C.G., 2019. Differences in pediatric and adult epilepsy surgery: A comparison at one center from 1990 to 2014.  Epilepsia 60, 233–245. https://doi​.org/10.1111/epi.14627 [PubMed: 30577071]
  30. Curran, M.M., Haddad, E., Patterson, K.P., Choy, M., Dubé, C.M., Baram, T.Z., Obenaus, A., 2018. Epilepsy-predictive magnetic resonance imaging changes following experimental febrile status epilepticus: Are they translatable to the clinic?  Epilepsia.  https://doi​.org/10.1111/epi.14561 [PMC free article: PMC6217797] [PubMed: 30256385]
  31. Dreier, J.W., Pedersen, C.B., Cotsapas, C., Christensen, J., 2019. Childhood seizures and risk of psychiatric disorders in adolescence and early adulthood: a Danish nationwide cohort study.  Lancet. Child Adolesc. Heal. 3, 99–108. https://doi​.org/10.1016​/S2352-4642(18)30351-1 [PMC free article: PMC6903917] [PubMed: 30528754]
  32. Dubé, C., Richichi, C., Bender, R.A., Chung, G., Litt, B., Baram, T.Z., 2006. Temporal lobe epilepsy after experimental prolonged febrile seizures: prospective analysis.  Brain 129, 911–22. https://doi​.org/10.1093/brain/awl018 [PMC free article: PMC3100674] [PubMed: 16446281]
  33. Dubé, C., Vezzani, A., Behrens, M., Bartfai, T., Baram, T.Z., 2005. Interleukin-1beta contributes to the generation of experimental febrile seizures.  Ann. Neurol. 57, 152–5. https://doi​.org/10.1002/ana.20358 [PMC free article: PMC2909879] [PubMed: 15622539]
  34. Dubé, C., Yu, H., Nalcioglu, O., Baram, T.Z., 2004. Serial MRI after experimental febrile seizures: altered T2 signal without neuronal death.  Ann. Neurol. 56, 709–14. https://doi​.org/10.1002/ana.20266 [PMC free article: PMC3084032] [PubMed: 15389889]
  35. Dubé, C.M., Brewster, A.L., Richichi, C., Zha, Q., Baram, T.Z., 2007. Fever, febrile seizures and epilepsy.  Trends Neurosci. 30, 490–6. https://doi​.org/10.1016/j​.tins.2007.07.006 [PMC free article: PMC2766556] [PubMed: 17897728]
  36. Dubé, C.M., Ravizza, T., Hamamura, M., Zha, Q., Keebaugh, A., Fok, K., Andres, A.L., Nalcioglu, O., Obenaus, A., Vezzani, A., Baram, T.Z., 2010. Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers.  J. Neurosci. 30, 7484–94. https://doi​.org/10.1523/JNEUROSCI​.0551-10.2010 [PMC free article: PMC2906240] [PubMed: 20519523]
  37. Dubé, C.M., Zhou, J., Hamamura, M., Zhao, Q., Ring, A., Abrahams, J., McIntyre, K., Nalcioglu, O., Shatskih, T., Baram, T.Z., Holmes, G.L., 2009. Cognitive dysfunction after experimental febrile seizures.  Exp. Neurol. 215, 167–177. https://doi​.org/10.1016/j​.expneurol.2008.10.003 [PMC free article: PMC2649663] [PubMed: 19000675]
  38. Eckhaus, J., Lawrence, K.M., Helbig, I., Bui, M., Vadlamudi, L., Hopper, J.L., Scheffer, I.E., Berkovic, S.F., 2013. Genetics of febrile seizure subtypes and syndromes: A twin study. Epilepsy Res. 105, 103–109. https://doi​.org/10.1016/j​.eplepsyres.2013.02.011 [PubMed: 23522981]
  39. Englot, D.J., Ouyang, D., Garcia, P.A., Barbaro, N.M., Chang, E.F., 2012. Epilepsy surgery trends in the United States, 1990-2008. Neurology. https://doi​.org/10.1212/WNL​.0b013e318250d7ea [PMC free article: PMC3324320] [PubMed: 22442428]
  40. Eskilsson, A., Mirrasekhian, E., Dufour, S., Schwaninger, M., Engblom, D., Blomqvist, A., 2014. Immune-Induced Fever Is Mediated by IL-6 Receptors on Brain Endothelial Cells Coupled to STAT3-Dependent Induction of Brain Endothelial Prostaglandin Synthesis.  J. Neurosci. 34, 15957–15961. https://doi​.org/10.1523/JNEUROSCI​.3520-14.2014 [PMC free article: PMC6608482] [PubMed: 25429137]
  41. Feng, B., Tang, Y., Chen, B., Xu, C., Wang, Y., Dai, Y., Wu, D., Zhu, J., Wang, S., Zhou, Y., Shi, L., Hu, W., Zhang, X., Chen, Z., 2016. Transient increase of interleukin-1β after prolonged febrile seizures promotes adult epileptogenesis through long-lasting upregulating endocannabinoid signaling. Sci. Rep. 6, 21931. https://doi​.org/10.1038/srep21931 [PMC free article: PMC4763292] [PubMed: 26902320]
  42. Frank, L.M., Shinnar, S., Hesdorffer, D.C., Shinnar, R.C., Pellock, J.M., Gallentine, W., Nordli, D.R., Epstein, L.G., Moshé, S.L., Lewis, D. V., Sun, S., 2012. Cerebrospinal Fluid Findings in Children with Fever-Associated Status Epilepticus: Results of the Consequences of Prolonged Febrile Seizures (FEBSTAT) Study.  J. Pediatr. 161, 1169–1171.e1. https://doi​.org/10.1016/j​.jpeds.2012.08.008 [PMC free article: PMC3504634] [PubMed: 22985722]
  43. French, J.A., Williamson, P.D., Thadani, V.M., Darcey, T.M., Mattson, R.H., Spencer, S.S., Spencer, D.D., 1993. Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination.  Ann. Neurol. 34, 774–80. https://doi​.org/10.1002/ana.410340604 [PubMed: 8250525]
  44. Fukuyama, Y., Seki, T., Ohtsuka, C., Miura, H., Hara, M., 1996. Practical guidelines for physicians in the management of febrile seizures.  Brain Dev. 18, 479–484. https://doi​.org/10.1016​/S0387-7604(96)00066-6 [PubMed: 8980847]
  45. Gaínza-Lein, M., Fernández, I.S., Jackson, M., Abend, Nicholas S., Arya, R., Nicholas Brenton, J., Carpenter, J.L., Chapman, K.E., Gaillard, W.D., Glauser, T.A., Goldstein, J.L., Goodkin, H.P., Kapur, K., Mikati, M.A., Peariso, K., Tasker, R.C., Tchapyjnikov, Dmitry, Topjian, A.A., Wainwright, M.S., Wilfong, A., Williams, K., Loddenkemper, T., Loddenkemper, T., Gaínza-Lein, M., Tasker, R.C., Sánchez Fernández, I., Clark, J., Jackson, M., Kapur, K., Abend, Nicolas S., Topjian, A.A., Gaillard, W.D., Carpenter, J., Wainstein, S., Dean, N., Sperberg, K., Glauser, T.A., Peariso, K., Arya, R., Clark, P., Chapman, K.E., Mikati, M.A., Tchapyjnikov, Dmrity, Helseth, A., Cornet, K., Turner, D., Wainwright, M.S., Goldstein, J.L., Rusie, A., Payne, E., Williams, K., Wilfong, A., Burrows, B., Anderson, A., Lai, Y.C., Nayak, A., Goodkin, H.P., Sacco, M., Zhu, H., Nicholas Brenton, J., 2018. Association of time to treatment with short-term outcomes for pediatric patients with refractory convulsive status epilepticus.  JAMA Neurol.  https://doi​.org/10.1001/jamaneurol​.2017.4382 [PMC free article: PMC5885266] [PubMed: 29356811]
  46. Gao, Z., Ure, K., Ding, P., Nashaat, M., Yuan, L., Ma, J., Hammer, R.E., Hsieh, J., 2011. The Master Negative Regulator REST/NRSF Controls Adult Neurogenesis by Restraining the Neurogenic Program in Quiescent Stem Cells.  J. Neurosci. 31, 9772–86. https://doi​.org/10.1523/JNEUROSCI​.1604-11.2011 [PMC free article: PMC3365553] [PubMed: 21715642]
  47. Garcia-Curran, M.M., Hall, A.M., Patterson, K.P., Shao, M., Eltom, N., Chen, K., Dubé, C.M., Baram, T.Z., 2019. Dexamethasone Attenuates Hyperexcitability Provoked by Experimental Febrile Status Epilepticus.  eNeuro. 2019 Nov 15;6(6): ENEURO.0430-19.2019 1–17. https://doi​.org/10.1523/ENEURO​.0430-19.2019 [PMC free article: PMC6860985] [PubMed: 31685676]
  48. Garriga-Canut, M., Schoenike, B., Qazi, R., Bergendahl, K., Daley, T.J., Pfender, R.M., Morrison, J.F., Ockuly, J., Stafstrom, C., Sutula, T., Roopra, A., 2006. 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP–dependent metabolic regulation of chromatin structure.  Nat. Neurosci. 9, 1382–1387. https://doi​.org/10.1038/nn1791 [PubMed: 17041593]
  49. Gaspard, N., Hirsch, L.J., Sculier, C., Loddenkemper, T., van Baalen, A., Lancrenon, J., Emmery, M., Specchio, N., Farias-Moeller, R., Wong, N., Nabbout, R., 2018. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives.  Epilepsia 59, 745–752. https://doi​.org/10.1111/epi.14022 [PubMed: 29476535]
  50. Glauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W.E., Garrity, L., Jagoda, A., Lowenstein, D., Pellock, J., Riviello, J., Sloan, E., Treiman, D.M., 2016. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.  Epilepsy Curr. 16, 48–61. https://doi​.org/10.5698/1535-7597-16​.1.48 [PMC free article: PMC4749120] [PubMed: 26900382]
  51. Guilliams, K., Rosen, M., Buttram, S., Zempel, J., Pineda, J., Miller, B., Shoykhet, M., 2013. Hypothermia for pediatric refractory status epilepticus.  Epilepsia. 2013 Sep;54(9):1586–94. https://doi​.org/10.1111/epi.12331 [PMC free article: PMC3975144] [PubMed: 23906244]
  52. Hall, A.M., Short, A.K., Singh-Taylor, A., Daglian, J., Mishina, T., Schmidt, W.K., Kouji, H., Baram, T.Z., 2018. NRSF–mediated repression of neuronal genes in developing brain persists in the absence of NRSF-Sin3 interaction.  bioRxiv 245993. https://doi​.org/10.1101/245993
  53. Haro, K., Igarashi, R., Hoshina, T., Kojiro, M., Kusuhara, K., 2018. Utility of the Performance of Lumbar Puncture for Febrile Children With Status Epilepticus in the Bacterial Conjugate Vaccine Era.  Pediatr. Infect. Dis. J. 2018 Oct;37(10): 963–966. https://doi​.org/10.1097/INF​.0000000000001945 [PubMed: 29461450]
  54. Hashimoto, R., Suto, M., Tsuji, M., Sasaki, H., Takehara, K., Ishiguro, A., Kubota, M., 2021. Use of antipyretics for preventing febrile seizure recurrence in children: a systematic review and meta-analysis.  Eur. J. Pediatr. 180, 987–997. https://doi​.org/10.1007​/s00431-020-03845-8 [PubMed: 33125519]
  55. Heida, J.G., Boissé, L., Pittman, Q.J., 2004. Lipopolysaccharide-induced febrile convulsions in the rat: short-term sequelae.  Epilepsia 45, 1317–29. https://doi​.org/10.1111/j​.0013-9580.2004.13704.x [PubMed: 15509232]
  56. Heida, J.G., Moshé, S.L., Pittman, Q.J., 2009. The role of interleukin-1beta in febrile seizures.  Brain Dev. 2009 May; 31(5): 388–93. https://doi​.org/10.1016/j​.braindev.2008.11.013 [PMC free article: PMC2699664] [PubMed: 19217733]
  57. Heida, J.G., Pittman, Q.J., 2005. Causal links between brain cytokines and experimental febrile convulsions in the rat.  Epilepsia 46, 1906–1913. https://doi​.org/10.1111/j​.1528-1167.2005.00294.x [PubMed: 16393156]
  58. Hesdorffer, D.C., Logroscino, G., Benn, E.K.T., Katri, N., Cascino, G., Hauser, W.A., 2011. Estimating risk for developing epilepsy: A population-based study in Rochester, Minnesota. Neurology 76, 23–27. https://doi​.org/10.1212/WNL​.0b013e318204a36a [PMC free article: PMC3032191] [PubMed: 21205691]
  59. Hesdorffer, D.C., Shinnar, S., Lax, D.N., Pellock, J.M., Nordli, D.R., Seinfeld, S., Gallentine, W., Frank, L.M., Lewis, D. V., Shinnar, R.C., Bello, J.A., Chan, S., Epstein, L.G., Moshé, S.L., Liu, B., Sun, S., 2016. Risk factors for subsequent febrile seizures in the FEBSTAT study.  Epilepsia 57, 1042–1047. https://doi​.org/10.1111/epi.13418 [PMC free article: PMC4935556] [PubMed: 27265870]
  60. Hirose, S., Scheffer, I.E., Marini, C., De Jonghe, P., Andermann, E., Goldman, A.M., Kauffman, M., Tan, N.C.K., Lowenstein, D.H., Sisodiya, S.M., Ottman, R., Berkovic, S.F., Genetics Commission of the International League Against Epilepsy, 2013. SCN1A testing for epilepsy: application in clinical practice.  Epilepsia 54, 946–52. https://doi​.org/10.1111/epi.12168 [PubMed: 23586701]
  61. Hirsch, L.J., Gaspard, N., van Baalen, A., Nabbout, R., Demeret, S., Loddenkemper, T., Navarro, V., Specchio, N., Lagae, L., Rossetti, A.O., Hocker, S., Gofton, T.E., Abend, N.S., Gilmore, E.J., Hahn, C., Khosravani, H., Rosenow, F., Trinka, E., 2018. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.  Epilepsia 59, 739–744. https://doi​.org/10.1111/epi.14016 [PubMed: 29399791]
  62. Holtman, L., Van Vliet, E. a., Edelbroek, P.M., Aronica, E., Gorter, J. a., 2010. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy.  Epilepsy Res. 91, 49–56. https://doi​.org/10.1016/j​.eplepsyres.2010.06.011 [PubMed: 20643531]
  63. Ichiyama, T., Suenaga, N., Kajimoto, M., Tohyama, J., Isumi, H., Kubota, M., Mori, M., Furukawa, S., 2008. Serum and CSF levels of cytokines in acute encephalopathy following prolonged febrile seizures.  Brain Dev. 2008 Jan;30(1):47–52. https://doi​.org/10.1016/j​.braindev.2007.05.008 [PubMed: 17597322]
  64. Inoue, M., Adachi, S., Kawakami, I., Koga, H., 2020. Change in the strategy for prophylactic diazepam use for febrile seizures and the impact on seizure recurrence within 24 h.  Seizure 75, 70–74. https://doi​.org/10.1016/j​.seizure.2019.12.021 [PubMed: 31884051]
  65. Järvelä, J.T., Ruohonen, S., Kukko-Lukjanov, T.K., Plysjuk, A., Lopez-Picon, F.R., Holopainen, I.E., 2011. Kainic acid-induced neurodegeneration and activation of inflammatory processes in organotypic hippocampal slice cultures: Treatment with cyclooxygenase-2 inhibitor does not prevent neuronal death.  Neuropharmacology 60, 1116–1125. https://doi​.org/10.1016/j​.neuropharm.2010.09.024 [PubMed: 20932983]
  66. Jehi, L., Friedman, D., Carlson, C., Cascino, G., Dewar, S., Elger, C., Engel, J., Knowlton, R., Kuzniecky, R., McIntosh, A., O’Brien, T.J., Spencer, D., Sperling, M.R., Worrell, G., Bingaman, B., Gonzalez-Martinez, J., Doyle, W., French, J., 2015. The evolution of epilepsy surgery between 1991 and 2011 in nine major epilepsy centers across the United States, Germany, and Australia.  Epilepsia. 2015 Oct;56(10):1526–33. https://doi​.org/10.1111/epi.13116 [PMC free article: PMC5082694] [PubMed: 26250432]
  67. Jiang, J., Ganesh, T., Du, Y., Quan, Y., Serrano, G., Qui, M., Speigel, I., Rojas, a., Lelutiu, N., Dingledine, R., 2012. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.  Proc. Natl. Acad. Sci. 109, 3149–3154. https://doi​.org/10.1073/pnas.1120195109 [PMC free article: PMC3286971] [PubMed: 22323596]
  68. Jiang, J., Ganesh, T., Du, Y., Thepchatri, P., Rojas, A., Lewis, I., Kurtkaya, S., Li, L., Qui, M., Serrano, G., Shaw, R., Sun, A., Dingledine, R., 2010. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.  Proc. Natl. Acad. Sci. U. S. A. 107, 2307–2312. https://doi​.org/10.1073/pnas.0909310107 [PMC free article: PMC2836658] [PubMed: 20080612]
  69. Jiang, J., Yang, M., Quan, Y., Gueorguieva, P., Ganesh, T., Dingledine, R., 2015. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.  Neurobiol. Dis. 76, 126–136. https://doi​.org/10.1016/j​.nbd.2014.12.032 [PMC free article: PMC4408774] [PubMed: 25600211]
  70. Jobst, B.C., Ben-Menachem, E., Chapman, K.E., Fu, A., Goldman, A., Hirsch, L.J., Jehi, L.E., Kossoff, E.H., Plueger, M., Rho, J.M., Schevon, C.A., Shinnar, S., Sperling, M.R., Simeone, T.A., Wagner, J.L., Lado, F., 2019. Highlights From the Annual Meeting of the American Epilepsy Society 2018.  Epilepsy Curr. 19, 152–158. https://doi​.org/10.1177/1535759719844486 [PMC free article: PMC6610384] [PubMed: 31050308]
  71. Jobst, B.C., Cascino, G.D., 2015. Resective epilepsy surgery for drug-resistant focal epilepsy: a review.  JAMA 313, 285–93. https://doi​.org/10.1001/jama.2014.17426 [PubMed: 25602999]
  72. Joshi, S., Goodkin, H.P., 2020. The Need to Intervene Before Time Point 2: Evidence From Clinical and Animal Data That Status Epilepticus Damages the Brain.  J. Clin. Neurophysiol. 37, 375–380. https://doi​.org/10.1097/WNP​.0000000000000711 [PubMed: 32890057]
  73. Kapur, J., Elm, J., Chamberlain, J.M., Barsan, W., Cloyd, J., Lowenstein, D., Shinnar, S., Conwit, R., Meinzer, C., Cock, H., Fountain, N., Connor, J.T., Silbergleit, R., 2019. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.  N. Engl. J. Med. 381, 2103–2113. https://doi​.org/10.1056/NEJMoa1905795 [PMC free article: PMC7098487] [PubMed: 31774955]
  74. Kasperavičiūtė, D., Catarino, C.B., Matarin, M., Leu, C., Novy, J., Tostevin, A., Leal, B., Hessel, E.V.S., Hallmann, K., Hildebrand, M.S., Dahl, H.-H.M., Ryten, M., Trabzuni, D., Ramasamy, A., Alhusaini, S., Doherty, C.P., Dorn, T., Hansen, J., Krämer, G., Steinhoff, B.J., Zumsteg, D., Duncan, S., Kälviäinen, R.K., Eriksson, K.J., Kantanen, A.-M., Pandolfo, M., Gruber-Sedlmayr, U., Schlachter, K., Reinthaler, E.M., Stogmann, E., Zimprich, F., Théâtre, E., Smith, C., O’Brien, T.J., Meng Tan, K., Petrovski, S., Robbiano, A., Paravidino, R., Zara, F., Striano, P., Sperling, M.R., Buono, R.J., Hakonarson, H., Chaves, J., Costa, P.P., Silva, B.M., da Silva, A.M., de Graan, P.N.E., Koeleman, B.P.C., Becker, A., Schoch, S., von Lehe, M., Reif, P.S., Rosenow, F., Becker, F., Weber, Y., Lerche, H., Rössler, K., Buchfelder, M., Hamer, H.M., Kobow, K., Coras, R., Blumcke, I., Scheffer, I.E., Berkovic, S.F., Weale, M.E., Delanty, N., Depondt, C., Cavalleri, G.L., Kunz, W.S., Sisodiya, S.M., Kasperaviciute, D., Catarino, C.B., Matarin, M., Leu, C., Novy, J., Tostevin, A., Leal, B., Hessel, E.V.S., Hallmann, K., Hildebrand, M.S., Dahl, H.-H.M., Ryten, M., Trabzuni, D., Ramasamy, A., Alhusaini, S., Doherty, C.P., Dorn, T., Hansen, J., Krämer, G., Steinhoff, B.J., Zumsteg, D., Duncan, S., Kälviäinen, R.K., Eriksson, K.J., Kantanen, A.-M., Pandolfo, M., Gruber-Sedlmayr, U., Schlachter, K., Reinthaler, E.M., Stogmann, E., Zimprich, F., Théâtre, E., Smith, C., O’Brien, T.J., Meng Tan, K., Petrovski, S., Robbiano, A., Paravidino, R., Zara, F., Striano, P., Sperling, M.R., Buono, R.J., Hakonarson, H., Chaves, J., Costa, P.P., Silva, B.M., da Silva, A.M., de Graan, P.N.E., Koeleman, B.P.C., Becker, A., Schoch, S., von Lehe, M., Reif, P.S., Rosenow, F., Becker, F., Weber, Y., Lerche, H., Rössler, K., Buchfelder, M., Hamer, H.M., Kobow, K., Coras, R., Blumcke, I., Scheffer, I.E., Berkovic, S.F., Weale, M.E., UK Brain Expression Consortium, Delanty, N., Depondt, C., Cavalleri, G.L., Kunz, W.S., Sisodiya, S.M., 2013. Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A. Brain 136, 3140–50. https://doi​.org/10.1093/brain/awt233 [PMC free article: PMC3784283] [PubMed: 24014518]
  75. Kothur, K., Bandodkar, S., Wienholt, L., Chu, S., Pope, A., Gill, D., Dale, R.C., 2019. Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus.  Epilepsia 60, 1678–1688. https://doi​.org/10.1111/epi.16275 [PubMed: 31283843]
  76. Lahat, E., Goldman, M., Barr, J., Bistritzer, T., Berkovitch, M., 2000. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: Prospective randomised study.  Br. Med. J. 321, 83–6. https://doi​.org/10.1136/bmj.321.7253.83 [PMC free article: PMC27427] [PubMed: 10884257]
  77. Lewis, D. V, Shinnar, S., Hesdorffer, D.C., Bagiella, E., Bello, J. a, Chan, S., Xu, Y., MacFall, J., Gomes, W. a, Moshé, S.L., Mathern, G.W., Pellock, J.M., Nordli, D.R., Frank, L.M., Provenzale, J., Shinnar, R.C., Epstein, L.G., Masur, D., Litherland, C., Sun, S., 2014. Hippocampal sclerosis after febrile status epilepticus: the FEBSTAT study.  Ann. Neurol. 75, 178–85. https://doi​.org/10.1002/ana.24081 [PMC free article: PMC3980500] [PubMed: 24318290]
  78. Li, Z., Li, B., Zhu, X., Yin, P., Liu, J., Huang, S., Sun, R., 2013. Neuroprotective effects of anti-high-mobility group box 1 antibody in juvenile rat hippocampus after kainic acid-induced status epilepticus.  Neuroreport 24, 785–90. https://doi​.org/10.1097/WNR​.0b013e328363fed3 [PubMed: 23839305]
  79. Lin, J.-J., Wang, Y., Lan, S.-Y., Chan, O.-W., Hsia, S.-H., Chou, M.-L., Hung, P.-C., Hsieh, M.-Y., Chou, I.-J., Wang, H.-S., Lin, K.-L., CHEESE Study Group, 2018. Combination of intravenous immunoglobulin and steroid pulse therapy improves outcomes of febrile refractory status epilepticus.  Epilepsy Res. 142, 100–105. https://doi​.org/10.1016/j​.eplepsyres.2018.03.017 [PubMed: 29609074]
  80. Luheshi, G.N., Stefferl, A., Turnbull, A. V, Dascombe, M.J., Brouwer, S., Hopkins, S.J., Rothwell, N.J., 1997. Febrile response to tissue inflammation involves both peripheral and brain IL-1 and TNF-alpha in the rat.  Am. J. Physiol. 272, R862–8. [PubMed: 9087648]
  81. Maroso, M., Balosso, S., Ravizza, T., Iori, V., Wright, C.I., French, J., Vezzani, A., 2011. Interleukin-1β Biosynthesis Inhibition Reduces Acute Seizures and Drug Resistant Chronic Epileptic Activity in Mice. Neurotherapeutics 8, 304–315. https://doi​.org/10.1007​/s13311-011-0039-z [PMC free article: PMC3101825] [PubMed: 21431948]
  82. Martinos, M.M., Pujar, S., O’Reilly, H., de Haan, M., Neville, B.G.R., Scott, R.C., Chin, R.F.M., 2019. Intelligence and memory outcomes within 10 years of childhood convulsive status epilepticus.  Epilepsy Behav. 95, 18–25. https://doi​.org/10.1016/j​.yebeh.2019.03.039 [PMC free article: PMC6586081] [PubMed: 31009825]
  83. Martinos, M.M., Yoong, M., Patil, S., Chin, R.F.M., Neville, B.G., Scott, R.C., De Haan, M., 2012. Recognition memory is impaired in children after prolonged febrile seizures.  Brain 135, 3153–3164. https://doi​.org/10.1093/brain/aws213 [PMC free article: PMC3470707] [PubMed: 22945967]
  84. Martinos, M.M., Yoong, M., Patil, S., Chong, W.K., Mardari, R., Chin, R.F.M., Neville, B.G.R., De Haan, M., Scott, R.C., 2013. Early developmental outcomes in children following convulsive status epilepticus: A longitudinal study.  Epilepsia 54, 1012–1019. https://doi​.org/10.1111/epi.12136 [PubMed: 23566067]
  85. McClelland, A.C., Gomes, W.A., Shinnar, S., Hesdorffer, D.C., Bagiella, E., Lewis, D. V, Bello, J.A., Chan, S., MacFall, J., Chen, M., Pellock, J.M., Nordli, D.R., Frank, L.M., Moshé, S.L., Shinnar, R.C., Sun, S., FEBSTAT Study Team, 2016. Quantitative Evaluation of Medial Temporal Lobe Morphology in Children with Febrile Status Epilepticus: Results of the FEBSTAT Study.  AJNR. Am. J. Neuroradiol. 37, 2356–2362. https://doi​.org/10.3174/ajnr.A4919 [PMC free article: PMC5161621] [PubMed: 27633809]
  86. McClelland, S., Brennan, G.P., Dubé, C., Rajpara, S., Iyer, S., Richichi, C., Bernard, C., Baram, T.Z., 2014. The transcription factor NRSF contributes to epileptogenesis by selective repression of a subset of target genes. Elife 3, e01267. [PMC free article: PMC4129437] [PubMed: 25117540]
  87. Mewasingh, L.D., Chin, R.F.M., Scott, R.C., 2020. Current understanding of febrile seizures and their long-term outcomes.  Dev. Med. Child Neurol. 62, 1245–1249. https://doi​.org/10.1111/dmcn.14642 [PubMed: 32748466]
  88. Mohammadpour Touserkani, F., Gaínza-Lein, M., Jafarpour, S., Brinegar, K., Kapur, K., Loddenkemper, T., 2017. HHV-6 and seizure: A systematic review and meta-analysis.  J. Med. Virol. 89, 161–169. https://doi​.org/10.1002/jmv.24594 [PubMed: 27272972]
  89. Murata, S., Okasora, K., Tanabe, T., Ogino, M., Yamazaki, S., Oba, C., Syabana, K., Nomura, S., Shirasu, A., Inoue, K., Kashiwagi, M., Tamai, H., 2018. Acetaminophen and Febrile Seizure Recurrences During the Same Fever Episode.  Pediatrics 142, e20181009. https://doi​.org/10.1542/peds.2018-1009 [PubMed: 30297499]
  90. Nagase, H., Nakagawa, T., Aoki, K., Fujita, K., Saji, Y., Maruyama, A., Uetani, Y., 2013. Therapeutic indicators of acute encephalopathy in patients with complex febrile seizures.  Pediatr. Int. 55, 310–314. https://doi​.org/10.1111/ped.12046 [PubMed: 23279186]
  91. Nagase, H., Nishiyama, M., Nakagawa, T., Fujita, K., Saji, Y., Maruyama, A., 2014. Midazolam fails to prevent neurological damage in children with convulsive refractory febrile status epilepticus.  Pediatr. Neurol. 51, 78–84. https://doi​.org/10.1016/j​.pediatrneurol.2014.02.021 [PubMed: 24830769]
  92. Nakken, K.O., Lossius, M.I., 2011. Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus.  Acta Neurol. Scand. 2011 Aug;124(2):99–103. https://doi​.org/10.1111/j​.1600-0404.2010.01474.x [PubMed: 21208198]
  93. Nickels, K.C., Zaccariello, M.J., Hamiwka, L.D., Wirrell, E.C., 2016. Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.  Nat. Rev. Neurol. 12, 465–476. https://doi​.org/10.1038/nrneurol.2016.98 [PubMed: 27448186]
  94. Nishiyama, M., Nagase, H., Tomioka, K., Tanaka, T., Yamaguchi, H., Ishida, Y., Toyoshima, D., Fujita, K., Maruyama, A., Kurosawa, H., Uetani, Y., Nozu, K., Taniguchi-Ikeda, M., Morioka, I., Takada, S., Iijima, K., 2018. Fosphenytoin vs. continuous midazolam for pediatric febrile status epilepticus.  Brain Dev. 40, 884–890. https://doi​.org/10.1016/j​.braindev.2018.08.001 [PubMed: 30144969]
  95. Noe, F.M., Polascheck, N., Frigerio, F., Bankstahl, M., Ravizza, T., Marchini, S., Beltrame, L., Banderó, C.R., Löscher, W., Vezzani, A., 2013. Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol. Dis. 59, 183–193. https://doi​.org/10.1016/j​.nbd.2013.07.015 [PubMed: 23938763]
  96. O’Dell, C., Shinnar, S., Ballaban-Gil, K.R., Hornick, M., Sigalova, M., Kang, H., Moshé, S.L., 2005. Rectal Diazepam Gel in the Home Management of Seizures in Children.  Pediatr. Neurol. 33, 166–172. https://doi​.org/10.1016/j​.pediatrneurol.2005.03.005 [PubMed: 16139730]
  97. Offringa, M., Newton, R., Cozijnsen, M.A., Nevitt, S.J., 2017. Prophylactic drug management for febrile seizures in children.  Cochrane Database Syst. Rev. 2017. Feb 22;2(2):CD003031. https://doi​.org/10.1002/14651858​.CD003031.pub3 [PMC free article: PMC6464693] [PubMed: 28225210]
  98. Patterson, K.P., Barry, J.M., Curran, M.M., Singh-Taylor, A., Brennan, G., Rismanchi, N., Page, M., Noam, Y., Holmes, G.L., Baram, T.Z., 2017. Enduring memory impairments provoked by developmental febrile seizures are mediated by functional and structural effects of neuronal restrictive silencing factor.  J. Neurosci. 2017 Apr 5;37(14):3799–3812. https://doi​.org/10.1523/JNEUROSCI​.3748-16.2017 [PMC free article: PMC5394897] [PubMed: 28275159]
  99. Patterson, K.P., Brennan, G.P., Curran, M., Kinney-lang, E., Dubé, C., Ly, C., Obenaus, A., Baram, T.Z., 2015. Rapid, Coordinate Inflammatory Responses after Experimental Febrile Status Epilepticus: Implications for Epileptogenesis.  eNeuro 2, 1–12. https://doi​.org/http://dx​.doi.org/10.1523/ENEURO​.0034-15.2015 [PMC free article: PMC4699830] [PubMed: 26730400]
  100. Polascheck, N., Bankstahl, M., Löscher, W., 2010. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy.  Exp. Neurol. 224, 219–233. https://doi​.org/10.1016/j​.expneurol.2010.03.014 [PubMed: 20353773]
  101. Provenzale, J.M., Barboriak, D.P., VanLandingham, K., MacFall, J., Delong, D., Lewis, D. V., 2008. Hippocampal MRI Signal Hyperintensity After Febrile Status Epilepticus Is Predictive of Subsequent Mesial Temporal Sclerosis.  Am. J. Roentgenol. 2008 Apr;190(4): 976–983. https://doi​.org/10.2214/AJR.07.2407 [PubMed: 18356445]
  102. Pujar, S.S., Martinos, M.M., Cortina-Borja, M., Chong, W.K.K., De Haan, M., Gillberg, C., Neville, B.G., Scott, R.C., Chin, R.F., North London Epilepsy Research Network, 2018. Long-term prognosis after childhood convulsive status epilepticus: a prospective cohort study.  Lancet. Child Adolesc. Heal. 2, 103–111. https://doi​.org/10.1016​/S2352-4642(17)30174-8 [PubMed: 30169233]
  103. Ravizza, T., Gagliardi, B., Noé, F., Boer, K., Aronica, E., Vezzani, A., 2008. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: Evidence from experimental models and human temporal lobe epilepsy.  Neurobiol. Dis. 29, 142–160. https://doi​.org/10.1016/j​.nbd.2007.08.012 [PubMed: 17931873]
  104. Reid, A.Y., Riazi, K., Campbell Teskey, G., Pittman, Q.J., 2013. Increased excitability and molecular changes in adult rats after a febrile seizure.  Epilepsia 54, e45–8. https://doi​.org/10.1111/epi.12061 [PubMed: 23293960]
  105. Rodenas-Ruano, A., Chávez, A.E., Cossio, M.J., Castillo, P.E., Zukin, R.S., 2012. REST-dependent epigenetic remodeling promotes the developmental switch in synaptic NMDA receptors.  Nat. Neurosci. 15, 1382–1390. https://doi​.org/10.1038/nn.3214 [PMC free article: PMC3501125] [PubMed: 22960932]
  106. Rojas, A., Jiang, J., Ganesh, T., Yang, M.S., Lelutiu, N., Gueorguieva, P., Dingledine, R., 2014. Cyclooxygenase-2 in epilepsy.  Epilepsia 55, 17–25. https://doi​.org/10.1111/epi.12461 [PMC free article: PMC3956447] [PubMed: 24446952]
  107. Roopra, A., Huang, Y., Dingledine, R., 2001. Neurological disease: listening to gene silencers.  Mol. Interv. 1, 219–28. [PubMed: 14993344]
  108. Sánchez Fernández, I., Abend, N.S., Amengual-Gual, M., Anderson, A., Arya, R., Barcia Aguilar, C., Brenton, J.N., Carpenter, J.L., Chapman, K.E., Clark, J., Farias-Moeller, R., Gaillard, W.D., Gaínza-Lein, M., Glauser, T., Goldstein, J., Goodkin, H.P., Guerriero, R.M., Lai, Y.-C., McDonough, T., Mikati, M.A., Morgan, L.A., Novotny, E., Payne, E., Peariso, K., Piantino, J., Ostendorf, A., Sands, T.T., Sannagowdara, K., Tasker, R.C., Tchapyjnikov, D., Topjian, A.A., Vasquez, A., Wainwright, M.S., Wilfong, A., Williams, K., Loddenkemper, T., 2020. Association of guideline publication and delays to treatment in pediatric status epilepticus.  Neurology 95, e1222–e1235. https://doi​.org/10.1212/WNL​.0000000000010174 [PMC free article: PMC7538224] [PubMed: 32611646]
  109. Scantlebury, M.H., Gibbs, S.A., Foadjo, B., Lema, P., Psarropoulou, C., Carmant, L., 2005. Febrile seizures in the predisposed brain: A new model of temporal lobe epilepsy.  Ann. Neurol.  https://doi​.org/10.1002/ana.20512 [PubMed: 15940665]
  110. Scheffer, I.E., Nabbout, R., 2019. SCN1A-related phenotypes: Epilepsy and beyond.  Epilepsia 60 Suppl 3, S17–S24. https://doi​.org/10.1111/epi.16386 [PubMed: 31904117]
  111. Schlessinger, a R., Cowan, W.M., Gottlieb, D.I., 1975. An autoradiographic study of the time of origin and the pattern of granule cell migration in the dentate gyrus of the rat.  J. Comp. Neurol. 159, 149–75. https://doi​.org/10.1002/cne.901590202 [PubMed: 1112911]
  112. Schoenherr, C.J., Anderson, D.J., 1995. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes.  Science 267, 1360–3. [PubMed: 7871435]
  113. Scott, R.C., Besag, F.M.C., Neville, B.G.R., 1999. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: A randomised trial.  Lancet.  https://doi​.org/10.1016​/S0140-6736(98)06425-3 [PubMed: 10030327]
  114. Scott, R.C., King, M.D., Gadian, D.G., Neville, B.G.R., Connelly, A., 2003. Hippocampal abnormalities after prolonged febrile convulsion: A longitudinal MRI study.  Brain 126, 2551–2557. https://doi​.org/10.1093/brain/awg262 [PubMed: 12937081]
  115. Seinfeld, S., Goodkin, H.P., Shinnar, S., 2016. Status Epilepticus.  Cold Spring Harb. Perspect. Med. 6, a022830. https://doi​.org/10.1101/cshperspect​.a022830 [PMC free article: PMC4772080] [PubMed: 26931807]
  116. Seinfeld, S., Shinnar, S., Sun, S., Hesdorffer, D.C., Deng, X., Shinnar, R.C., O’Hara, K., Nordli, D.R., Frank, L.M., Gallentine, W., Moshé, S.L., Pellock, J.M., 2014. Emergency management of febrile status epilepticus: Results of the FEBSTAT study.  Epilepsia 55, 388–395. https://doi​.org/10.1111/epi.12526 [PMC free article: PMC3959260] [PubMed: 24502379]
  117. Seinfeld, S.A., Pellock, J.M., Kjeldsen, M.J., Nakken, K.O., Corey, L.A., 2016. Epilepsy After Febrile Seizures: Twins Suggest Genetic Influence.  Pediatr. Neurol. 55, 14–6. https://doi​.org/10.1016/j​.pediatrneurol.2015.10.008 [PMC free article: PMC4747848] [PubMed: 26638777]
  118. Shinnar, S., Bello, J.A., Chan, S., Hesdorffer, D.C., Lewis, D. V, Macfall, J., Pellock, J.M., Nordli, D.R., Frank, L.M., Moshe, S.L., Gomes, W., Shinnar, R.C., Sun, S., 2012. MRI abnormalities following febrile status epilepticus in children: the FEBSTAT study.  Neurology 79, 871–7. https://doi​.org/10.1212/WNL​.0b013e318266fcc5 [PMC free article: PMC3425848] [PubMed: 22843278]
  119. Shinnar, S., Hesdorffer, D.C., Nordli, D.R., Pellock, J.M., O’Dell, C., Lewis, D. V, Frank, L.M., Moshé, S.L., Epstein, L.G., Marmarou, A., Bagiella, E., 2008. Phenomenology of prolonged febrile seizures: results of the FEBSTAT study.  Neurology 71, 170–6. https://doi​.org/10.1212/01​.wnl.0000310774.01185.97 [PubMed: 18525033]
  120. Shinnar, S., Pellock, J.M., Moshé, S.L., Maytal, J., O’Dell, C., Driscoll, S.M., Alemany, M., Newstein, D., DeLorenzo, R.J., 1997. In whom does status epilepticus occur: Age-related differences in children.  Epilepsia 38, 907–914. https://doi​.org/10.1111/j​.1528-1157.1997.tb01256.x [PubMed: 9579892]
  121. Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y., Barsan, W., 2012. Intramuscular versus intravenous therapy for prehospital status epilepticus.  N. Engl. J. Med.  https://doi​.org/10.1056/NEJMoa1107494 [PMC free article: PMC3307101] [PubMed: 22335736]
  122. Silverman, E.C., Sporer, K.A., Lemieux, J.M., Brown, J.F., Koenig, K.L., Gausche-Hill, M., Rudnick, E.M., Salvucci, A.A., Gilbert, G.H., 2017. Prehospital Care for the Adult and Pediatric Seizure Patient: Current Evidence-based Recommendations.  West. J. Emerg. Med. 18, 419–436. https://doi​.org/10.5811/westjem​.2016.12.32066 [PMC free article: PMC5391892] [PubMed: 28435493]
  123. Singh-Taylor, A., Molet, J., Jiang, S., Korosi, A., Bolton, J.L., Noam, Y., Simeone, K., Cope, J., Chen, Y., Mortazavi, A., Baram, T.Z., 2017. NRSF-dependent epigenetic mechanisms contribute to programming of stress-sensitive neurons by neonatal experience, promoting resilience.  Mol. Psychiatry.  https://doi​.org/10.1038/mp.2016.240 [PMC free article: PMC5503824] [PubMed: 28070121]
  124. Spencer, S.S., 2002. When should temporal-lobe epilepsy be treated surgically? Lancet Neurol. 1, 375–82. https://doi​.org/10.1016​/s1474-4422(02)00163-1 [PubMed: 12849399]
  125. Stafstrom, C.E., 2002. The Incidence and Prevalence of Febrile Seizures, in: Febrile Seizures. Elsevier, pp. 1–25. https://doi​.org/10.1016​/B978-012078141-6/50003-2
  126. Steering Committee on Quality Improvement and Management: Subcommittee on Febrile Seizures, 2008. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures.  Pediatrics 121, 1281–6. https://doi​.org/10.1542/peds.2008-0939 [PubMed: 18519501]
  127. Tao, K., Ichikawa, J., Matsuki, N., Ikegaya, Y., Koyama, R., 2016. Experimental febrile seizures induce age-dependent structural plasticity and improve memory in mice.  Neuroscience 318, 34–44. https://doi​.org/10.1016/j​.neuroscience.2016.01.011 [PubMed: 26794590]
  128. Theodore, W.H., Epstein, L., Gaillard, W.D., Shinnar, S., Wainwright, M.S., Jacobson, S., 2008. Human herpes virus 6B: a possible role in epilepsy? Epilepsia 49, 1828–37. https://doi​.org/10.1111/j​.1528-1167.2008.01699.x [PMC free article: PMC2694582] [PubMed: 18627418]
  129. Thind, K.K., Ribak, C.E., Buckmaster, P.S., 2008. Synaptic input to dentate granule cell basal dendrites in a rat model of temporal lobe epilepsy.  J. Comp. Neurol. 509, 190–202. https://doi​.org/10.1002/cne.21745 [PMC free article: PMC2667124] [PubMed: 18461605]
  130. Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A.O., Scheffer, I.E., Shinnar, S., Shorvon, S., Lowenstein, D.H., 2015. A definition and classification of status epilepticus—Report of the ILAE Task Force on Classification of Status Epilepticus.  Epilepsia 56, 1515–1523. https://doi​.org/10.1111/epi.13121 [PubMed: 26336950]
  131. Trivisano, M., Specchio, N., 2019. The role of PCDH19 in refractory status epilepticus.  Epilepsy Behav. 101, 106539. https://doi​.org/10.1016/j​.yebeh.2019.106539 [PubMed: 31678000]
  132. van Gassen, K.L.I., Hessel, E.V.S., Ramakers, G.M.J., Notenboom, R.G.E., Wolterink-Donselaar, I.G., Brakkee, J.H., Godschalk, T.C., Qiao, X., Spruijt, B.M., van Nieuwenhuizen, O., de Graan, P.N.E., 2008. Characterization of febrile seizures and febrile seizure susceptibility in mouse inbred strains.  Genes, Brain Behav. 7, 578–586. [PubMed: 18363854]
  133. Verity, C.M., Greenwood, R., Golding, J., 1998. Long-Term Intellectual and Behavioral Outcomes of Children with Febrile Convulsions.  N. Engl. J. Med. Jun 11;338(24): 1723–1728. https://doi​.org/10.1056​/NEJM199806113382403 [PubMed: 9624192]
  134. Vestergaard, M., Pedersen, C.B., Sidenius, P., Olsen, J., Christensen, J., 2007. The long-term risk of epilepsy after febrile seizures in susceptible subgroups.  Am. J. Epidemiol. 165, 911–8. https://doi​.org/10.1093/aje/kwk086 [PubMed: 17267419]
  135. Vezzani, A., French, J., Bartfai, T., Baram, T.Z., 2011. The role of inflammation in epilepsy.  Nat. Rev. Neurol. 7, 31–40. https://doi​.org/10.1038/nrneurol​.2010.178 [PMC free article: PMC3378051] [PubMed: 21135885]
  136. Weiss, E., DM, M., Shinnar, S., Hesdorffer, D., Lewis, D., Shinnar, R., Bello, J., Chan, S., Seinfeld, S., Gallentine, W., Frank, L., Epstein, L., Nordli, D., Moshé, S., J, Z., Sun, S., Team, T.F., 2017. Memory function following febrile status epilepticus: Results of the FEBSTAT Study, in: American Epilepsy Society Annual Meeting. Washington DC.
  137. Weiss, E.F., Masur, D., Shinnar, S., Hesdorffer, D.C., Hinton, V.J., Bonner, M., Rinaldi, J., Van de Water, V., Culbert, J., Shinnar, R.C., Seinfeld, S., Gallentine, W., Nordli, D.R., Frank, L.M., Epstein, L., Moshé, S.L., Sun, S., 2016. Cognitive functioning one month and one year following febrile status epilepticus.  Epilepsy Behav. 64, 283–288. https://doi​.org/10.1016/j​.yebeh.2016.09.013 [PMC free article: PMC5115943] [PubMed: 27794237]
  138. Wiebe, S., Blume, W.T., Girvin, J.P., Eliasziw, M., Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group, 2001. A randomized, controlled trial of surgery for temporal-lobe epilepsy.  N. Engl. J. Med. 345, 311–8. [PubMed: 11484687]
  139. Yokoi, S., Kidokoro, H., Yamamoto, H., Ohno, A., Nakata, T., Kubota, T., Tsuji, T., Morishita, M., Kawabe, T., Naiki, M., Maruyama, K., Itomi, K., Kato, T., Ito, K., Natsume, J., 2019. Hippocampal diffusion abnormality after febrile status epilepticus is related to subsequent epilepsy.  Epilepsia 60, 1306–1316. https://doi​.org/10.1111/epi.16059 [PubMed: 31166617]
  140. Zehtabchi, S., Silbergleit, R., Chamberlain, J.M., Shinnar, S., Elm, J.J., Underwood, E., Rosenthal, E.S., Bleck, T.P., Kapur, J., 2020. Electroencephalographic Seizures in Emergency Department Patients After Treatment for Convulsive Status Epilepticus.  J. Clin. Neurophysiol. Publish Ah. 2022 Sep 1;39(6):441–445. https://doi​.org/10.1097/WNP​.0000000000000800 [PMC free article: PMC8192587] [PubMed: 33337664]
Copyright Notice

This is an open access publication, available online and distributed under the terms of a Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International licence (CC BY-NC-ND 4.0), a copy of which is available at https://creativecommons.org/licenses/by-nc-nd/4.0/. Subject to this license, all rights are reserved.

Bookshelf ID: NBK609854PMID: 39637113DOI: 10.1093/med/9780197549469.003.0069

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (283M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...